Poltreg S.A. Logo

Poltreg S.A.

A clinical-stage biotech developing T-regulatory cell therapies for autoimmune diseases.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK

Description

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2022-12-27 19:15
Zawarcie aneksu do umowy na dofinasowanie projektu pn. "Centrum Badawczo - Rozw…
Polish HTML 1.2 KB
2022-12-10 18:55
Informacja nt. rekomendowania projektu konsorcjum do finansowania w ramach konk…
Polish HTML 2.4 KB
2022-11-25 19:54
Kwartalny raport finansowy Q3 2022
Polish PDF 2.6 MB
2022-11-22 18:29
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania pro…
Polish HTML 2.1 KB
2022-11-09 11:52
Zawarcie umowy dot. nabycia i instalacji infrastruktury laboratorium komercyjne…
Polish HTML 2.6 KB
2022-10-24 13:41
Zawarcie z Clinmark sp. z o.o. umowy ramowej na realizację badań klinicznych or…
Polish HTML 3.3 KB
2022-08-31 17:06
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Polish PDF 207.5 KB
2022-08-31 17:06
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czer…
Polish PDF 2.4 MB
2022-08-31 17:06
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2022 roku
Polish PDF 1.5 MB
2022-08-10 18:10
Zawarcie umowy o wspólności praw do uzyskania patentu i o wspólności praw z pat…
Polish HTML 2.8 KB
2022-07-06 19:45
Zawiadomienie od TFI Allianz Polska S.A. o zmianie udziału w ogólnej liczbie gł…
Polish HTML 2.9 KB
2022-06-24 13:36
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish HTML 1.5 KB
2022-06-24 13:32
treść uchwał podjętych podczas ZWZA PolTREG S.A. w dniu 24 czerwca 2022 roku
Polish PDF 308.4 KB
2022-06-24 13:32
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie PolTREG S.A. w dniu 2…
Polish HTML 1.4 KB
2022-06-22 15:54
Powołanie osób zarządzających na kolejną kadencję - Content (PL)
Polish HTML 5.1 KB

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Poltreg S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.